Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.

Ravi D. Rao, Joon H. Uhm, Sunil Krishnan, C. David James

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Glioblastomas multiforme (GBM) is the most common malignant primary brain tumor in adults. GBM patients have a dismal prognosis, with a median survival of less than 1 year. During the past decade, significant advances have been made in our understanding of the molecular pathogenesis of these tumors. Specific genetic defects have been identified that appear to be important for the development, as well as maintenance of the malignant characteristics that are associated with GBM. Some of these genetic aberrations appear to have prognostic significance. However, even more exciting in this era of molecularly targeted therapy are the clues these gene alterations provide for identifying signaling mechanisms responsible for carcinogenesis, and for identifying potential therapeutic targets. Cancer drug therapy is currently undergoing a major transition with an attempt to move from the use of cytotoxic drugs towards the use of tumor mechanism-based drugs. Advances such as the decoding of the human genome, combinatorial chemistry, and gene expression profiling have led to an increase in the rate at which new drugs are being developed. In this review, we will describe the most common genetic and signaling pathway alterations that have relevance to new drug development for the treatment of GBM.

Original languageEnglish (US)
JournalFrontiers in bioscience : a journal and virtual library
Volume8
StatePublished - 2003

Fingerprint

Glioblastoma
Tumors
Pharmaceutical Preparations
Genes
Drug therapy
Neoplasms
Gene Expression Profiling
Human Genome
Therapeutics
Aberrations
Gene expression
Brain Neoplasms
Genetic Therapy
Decoding
Brain
Carcinogenesis
Maintenance
Drug Therapy
Defects
Survival

Cite this

Genetic and signaling pathway alterations in glioblastoma : relevance to novel targeted therapies. / Rao, Ravi D.; Uhm, Joon H.; Krishnan, Sunil; James, C. David.

In: Frontiers in bioscience : a journal and virtual library, Vol. 8, 2003.

Research output: Contribution to journalReview article

@article{1bf6f962d9174f2aa394477409e85102,
title = "Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.",
abstract = "Glioblastomas multiforme (GBM) is the most common malignant primary brain tumor in adults. GBM patients have a dismal prognosis, with a median survival of less than 1 year. During the past decade, significant advances have been made in our understanding of the molecular pathogenesis of these tumors. Specific genetic defects have been identified that appear to be important for the development, as well as maintenance of the malignant characteristics that are associated with GBM. Some of these genetic aberrations appear to have prognostic significance. However, even more exciting in this era of molecularly targeted therapy are the clues these gene alterations provide for identifying signaling mechanisms responsible for carcinogenesis, and for identifying potential therapeutic targets. Cancer drug therapy is currently undergoing a major transition with an attempt to move from the use of cytotoxic drugs towards the use of tumor mechanism-based drugs. Advances such as the decoding of the human genome, combinatorial chemistry, and gene expression profiling have led to an increase in the rate at which new drugs are being developed. In this review, we will describe the most common genetic and signaling pathway alterations that have relevance to new drug development for the treatment of GBM.",
author = "Rao, {Ravi D.} and Uhm, {Joon H.} and Sunil Krishnan and James, {C. David}",
year = "2003",
language = "English (US)",
volume = "8",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Genetic and signaling pathway alterations in glioblastoma

T2 - relevance to novel targeted therapies.

AU - Rao, Ravi D.

AU - Uhm, Joon H.

AU - Krishnan, Sunil

AU - James, C. David

PY - 2003

Y1 - 2003

N2 - Glioblastomas multiforme (GBM) is the most common malignant primary brain tumor in adults. GBM patients have a dismal prognosis, with a median survival of less than 1 year. During the past decade, significant advances have been made in our understanding of the molecular pathogenesis of these tumors. Specific genetic defects have been identified that appear to be important for the development, as well as maintenance of the malignant characteristics that are associated with GBM. Some of these genetic aberrations appear to have prognostic significance. However, even more exciting in this era of molecularly targeted therapy are the clues these gene alterations provide for identifying signaling mechanisms responsible for carcinogenesis, and for identifying potential therapeutic targets. Cancer drug therapy is currently undergoing a major transition with an attempt to move from the use of cytotoxic drugs towards the use of tumor mechanism-based drugs. Advances such as the decoding of the human genome, combinatorial chemistry, and gene expression profiling have led to an increase in the rate at which new drugs are being developed. In this review, we will describe the most common genetic and signaling pathway alterations that have relevance to new drug development for the treatment of GBM.

AB - Glioblastomas multiforme (GBM) is the most common malignant primary brain tumor in adults. GBM patients have a dismal prognosis, with a median survival of less than 1 year. During the past decade, significant advances have been made in our understanding of the molecular pathogenesis of these tumors. Specific genetic defects have been identified that appear to be important for the development, as well as maintenance of the malignant characteristics that are associated with GBM. Some of these genetic aberrations appear to have prognostic significance. However, even more exciting in this era of molecularly targeted therapy are the clues these gene alterations provide for identifying signaling mechanisms responsible for carcinogenesis, and for identifying potential therapeutic targets. Cancer drug therapy is currently undergoing a major transition with an attempt to move from the use of cytotoxic drugs towards the use of tumor mechanism-based drugs. Advances such as the decoding of the human genome, combinatorial chemistry, and gene expression profiling have led to an increase in the rate at which new drugs are being developed. In this review, we will describe the most common genetic and signaling pathway alterations that have relevance to new drug development for the treatment of GBM.

UR - http://www.scopus.com/inward/record.url?scp=1542464928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542464928&partnerID=8YFLogxK

M3 - Review article

C2 - 12700121

AN - SCOPUS:1542464928

VL - 8

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -